EUCTR2010-019525-34-SE进行中（未招募）不适用
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA - ROSiA
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Female patients, >/=18 years of age
- •- Histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma or clear cell carcinoma or carcinosarcoma. Patients with recurrent ovarian cancer who have been previously treated with surgery alone for their early stage disease are eligible.
- •- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1 or 2
- •- Life expectancy >/=3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 610
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 390
排除标准
- •- Patients with non-epithelial ovarian cancer, ovarian tumors with low malignant potential (i.e. borderline tumors), or synchronous primary endometrial carcinoma
- •- Previous systemic therapy for ovarian cancer. Prior neo-adjuvant chemotherapy is allowed
- •- Planned intraperitoneal cytotoxic chemotherapy
- •- Radiotherapy within 28 days of Day 1, Cycle 1
- •- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to first dose of Avastin
- •- History or evidence of NCI CTCAE Grade =1 arterial thromboembolic event or Grade =3 venous thromboembolic event within the 6 months prior to enrolment
研究者
相似试验
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMAMedDRA version: 16.1Level: LLTClassification code 10052204Term: Ovarian carcinosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019525-34-BGF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEUCTR2010-019525-34-ATF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMAMedDRA version: 16.1Level: LLTClassification code 10052204Term: Ovarian carcinosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019525-34-HUF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
1 期
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA - ROSiAEPITHELIAL OVARIAN CANCERFALLOPIAN TUBE CARCINOMAPRIMARY PERITONEAL CARCINOMAMedDRA version: 12.1Level: LLTClassification code 10033128Term: Ovarian cancerMedDRA version: 12.1Level: LLTClassification code 10052204Term: Ovarian carcinosarcomaMedDRA version: 12.1Level: LLTClassification code 10016180Term: Fallopian tube cancerEUCTR2010-019525-34-FRF. Hoffmann-La Roche Ltd1,021
招募中
3 期
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMAovariancancerovariancarcinoma1003859410033283NL-OMON39830Roche Nederland B.V.40